Mandate

Vinge advises Mylan on its offer for Meda

February 12, 2016

Mylan N.V. has announced a recommended public offer to the shareholders of Meda AB (publ) to tender all their shares in Meda to Mylan. The total offer consideration consists of a combination of cash and Mylan ordinary shares. At announcement, the total value of the offer for all Meda shares, including Meda net debt, is approximately SEK 83.6 billion or USD 9.9 billion.
 
In connection with the offer, Mylan has retained Vinge as legal advisor in Sweden. The Vinge team is led by public M&A partners Erik Sjöman and Charlotte Levin and also includes Rikard Lindahl, Anna Edström and Malte Hedlund (on M&A matters), Mikael Ståhl, Louise Brorsson Salomon and Albert Wållgren (on finance matters), Fredrik Gustafsson (on compensation and benefits matters) and Maria Schultzberg (on tax matters).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026